Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7491312rdf:typepubmed:Citationlld:pubmed
pubmed-article:7491312lifeskim:mentionsumls-concept:C0028778lld:lifeskim
pubmed-article:7491312lifeskim:mentionsumls-concept:C0003195lld:lifeskim
pubmed-article:7491312lifeskim:mentionsumls-concept:C0178539lld:lifeskim
pubmed-article:7491312lifeskim:mentionsumls-concept:C0022009lld:lifeskim
pubmed-article:7491312lifeskim:mentionsumls-concept:C0178566lld:lifeskim
pubmed-article:7491312lifeskim:mentionsumls-concept:C0178499lld:lifeskim
pubmed-article:7491312lifeskim:mentionsumls-concept:C0430467lld:lifeskim
pubmed-article:7491312lifeskim:mentionsumls-concept:C1527178lld:lifeskim
pubmed-article:7491312pubmed:issue9 Pt 1lld:pubmed
pubmed-article:7491312pubmed:dateCreated1996-1-4lld:pubmed
pubmed-article:7491312pubmed:abstractTextAntiarrhythmic drugs have relative specificity for blocking each of the major classes of ion channels that control the action potential. The kinetics of block is determined by the state of the channel. Those channel states occupied at depolarized potentials generally have greater affinity for the blocking drugs. The kinetics of the drug-channel interaction is important in determining the blocking profile observed clinically. The increased mortality resulting from drug treatment in CAST and several atrial fibrillation trials has resulted in a shift in antiarrhythmic drug development from the Na+ channel blocking (Class I) drugs to the K+ channel blocking (Class III) drugs. While both Classes of drugs have a proarrhythmic potential, this may be less for the Class III agents. Their lack of negative inotropy also make them more attractive. It is important that the potential advantages of these agents be evaluated in controlled clinical trials. In several laboratories, the techniques of molecular biology and biophysics are being combined to determine the block site of available drugs. This information will aid in the future development of agents with greater specificity, and hopefully greater efficacy and safety than those currently in clinical use.lld:pubmed
pubmed-article:7491312pubmed:languageenglld:pubmed
pubmed-article:7491312pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7491312pubmed:citationSubsetIMlld:pubmed
pubmed-article:7491312pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7491312pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7491312pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7491312pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7491312pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7491312pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7491312pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7491312pubmed:statusMEDLINElld:pubmed
pubmed-article:7491312pubmed:monthSeplld:pubmed
pubmed-article:7491312pubmed:issn0147-8389lld:pubmed
pubmed-article:7491312pubmed:authorpubmed-author:GrantA OAOlld:pubmed
pubmed-article:7491312pubmed:authorpubmed-author:WendtD JDJlld:pubmed
pubmed-article:7491312pubmed:authorpubmed-author:WhalleyD WDWlld:pubmed
pubmed-article:7491312pubmed:issnTypePrintlld:pubmed
pubmed-article:7491312pubmed:volume18lld:pubmed
pubmed-article:7491312pubmed:ownerNLMlld:pubmed
pubmed-article:7491312pubmed:authorsCompleteYlld:pubmed
pubmed-article:7491312pubmed:pagination1686-704lld:pubmed
pubmed-article:7491312pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:7491312pubmed:meshHeadingpubmed-meshheading:7491312-...lld:pubmed
pubmed-article:7491312pubmed:meshHeadingpubmed-meshheading:7491312-...lld:pubmed
pubmed-article:7491312pubmed:meshHeadingpubmed-meshheading:7491312-...lld:pubmed
pubmed-article:7491312pubmed:meshHeadingpubmed-meshheading:7491312-...lld:pubmed
pubmed-article:7491312pubmed:meshHeadingpubmed-meshheading:7491312-...lld:pubmed
pubmed-article:7491312pubmed:meshHeadingpubmed-meshheading:7491312-...lld:pubmed
pubmed-article:7491312pubmed:meshHeadingpubmed-meshheading:7491312-...lld:pubmed
pubmed-article:7491312pubmed:meshHeadingpubmed-meshheading:7491312-...lld:pubmed
pubmed-article:7491312pubmed:meshHeadingpubmed-meshheading:7491312-...lld:pubmed
pubmed-article:7491312pubmed:meshHeadingpubmed-meshheading:7491312-...lld:pubmed
pubmed-article:7491312pubmed:meshHeadingpubmed-meshheading:7491312-...lld:pubmed
pubmed-article:7491312pubmed:meshHeadingpubmed-meshheading:7491312-...lld:pubmed
pubmed-article:7491312pubmed:meshHeadingpubmed-meshheading:7491312-...lld:pubmed
pubmed-article:7491312pubmed:year1995lld:pubmed
pubmed-article:7491312pubmed:articleTitleBasic concepts in cellular cardiac electrophysiology: Part II: Block of ion channels by antiarrhythmic drugs.lld:pubmed
pubmed-article:7491312pubmed:affiliationDuke University Medical Center, Durham, North Carolina, USA.lld:pubmed
pubmed-article:7491312pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7491312pubmed:publicationTypeReviewlld:pubmed
pubmed-article:7491312pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7491312lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7491312lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7491312lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7491312lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7491312lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7491312lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7491312lld:pubmed